Insmed Incorporated (NASDAQ:INSM) Holdings Reduced by Emerald Advisers LLC

Emerald Advisers LLC cut its stake in Insmed Incorporated (NASDAQ:INSM - Free Report) by 0.7% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 684,636 shares of the biopharmaceutical company's stock after selling 5,171 shares during the quarter. Insmed comprises about 1.8% of Emerald Advisers LLC's holdings, making the stock its 6th largest position. Emerald Advisers LLC owned 0.38% of Insmed worth $47,267,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Steward Partners Investment Advisory LLC boosted its holdings in Insmed by 65.2% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company's stock valued at $29,000 after purchasing an additional 163 shares during the period. V Square Quantitative Management LLC raised its position in shares of Insmed by 60.3% in the fourth quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company's stock worth $45,000 after buying an additional 248 shares in the last quarter. Spire Wealth Management bought a new stake in Insmed during the fourth quarter valued at $47,000. Smartleaf Asset Management LLC grew its position in Insmed by 98.1% during the fourth quarter. Smartleaf Asset Management LLC now owns 830 shares of the biopharmaceutical company's stock worth $57,000 after buying an additional 411 shares in the last quarter. Finally, Venturi Wealth Management LLC bought a new position in Insmed in the 4th quarter worth about $86,000.

Insmed Stock Up 1.5 %

Shares of NASDAQ:INSM traded up $1.12 during midday trading on Thursday, reaching $77.69. The company's stock had a trading volume of 1,139,707 shares, compared to its average volume of 2,179,246. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03. The firm has a 50 day moving average of $78.07 and a 200-day moving average of $73.93. The firm has a market capitalization of $14.06 billion, a P/E ratio of -13.90 and a beta of 1.28. Insmed Incorporated has a 12-month low of $21.92 and a 12-month high of $84.91.

Remove Ads

Insmed (NASDAQ:INSM - Get Free Report) last posted its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.32) EPS for the quarter, missing the consensus estimate of ($1.17) by ($0.15). Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. The business had revenue of $104.44 million for the quarter, compared to the consensus estimate of $102.31 million. On average, research analysts anticipate that Insmed Incorporated will post -4.56 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages have issued reports on INSM. Guggenheim reiterated a "buy" rating and set a $101.00 target price on shares of Insmed in a research report on Tuesday, February 25th. Stifel Nicolaus dropped their price objective on shares of Insmed from $97.00 to $96.00 and set a "buy" rating for the company in a report on Friday, February 21st. UBS Group raised their price target on Insmed from $105.00 to $110.00 and gave the company a "buy" rating in a research report on Thursday, March 6th. JPMorgan Chase & Co. upped their price objective on Insmed from $83.00 to $92.00 and gave the stock an "overweight" rating in a report on Friday, February 7th. Finally, HC Wainwright reiterated a "buy" rating and set a $90.00 price objective on shares of Insmed in a research report on Friday, February 21st. One analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $94.00.

Insider Buying and Selling

In other news, CFO Sara Bonstein sold 1,066 shares of Insmed stock in a transaction dated Friday, January 10th. The stock was sold at an average price of $63.72, for a total value of $67,925.52. Following the completion of the transaction, the chief financial officer now owns 118,863 shares of the company's stock, valued at $7,573,950.36. The trade was a 0.89 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO William Lewis sold 18,750 shares of the stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $69.84, for a total transaction of $1,309,500.00. Following the sale, the chief executive officer now directly owns 384,960 shares in the company, valued at $26,885,606.40. This trade represents a 4.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 550,957 shares of company stock worth $42,992,528 in the last 90 days. Insiders own 4.60% of the company's stock.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.